Lancet study finds no benefit for hydroxychloroquine in Covid-19 patients

0
8


Remedy for Covid-19 with the antimalarial drug hydroxychloroquine, either without or with the antibiotic azithromycin, offers no benefit for Covid-19 patients, according to a large observational study.


The research, published in the publication The Lancet, analysed data from almost 15,000 patients with Covid-19 who received chloroquine or its analogue hydroxychloroquine, taken without or with the antibiotics azithromycin or clarithromycin, and 81,000 controls.


According to the researchers, including Mandeep Mehra from Brigham and Women’s Hospital in america, Covid-19 patients on these drug regimens, experienced an increased risk of serious heart rhythm complications.


ALSO READ: Coronavirus LIVE: NDRF reports 1st case, 43 new infections in paramilitary


The scientists said these drugs must not be used to treat Covid-19 patients outdoor of clinical trials until results from randomised clinical trials are to be had to confirm their safety and efficacy for Covid-19 patients.


They explained chloroquine, an antimalarial drug and its analogue, hydroxychloroquine, are commonly used to treat autoimmune diseases including lupus and arthritis.


Both these drugs have a good safety profile as treatments for those particular conditions, and the current research said these patients must not stop taking these drugs whether they’re prescribed for approved conditions.


While these drugs have shown antiviral effects in laboratory tests, and are of interest as potential treatments against SARS-CoV-2, the current study has found that they don’t benefit patients undergoing remedy for Covid-19.


“This is the first large scale study to find statistically robust evidence that remedy with chloroquine or hydroxychloroquine does not benefit patients with Covid-19,” Mehra said.


ALSO READ: GAIL steel pipe tenders worth Rs 1,000 cr in process under going-local plan


According to Mehra, the findings propose the drugs is also associated with an increased risk of serious heart problems and increased risk of death.


“Randomised clinical trials are fundamental to confirm any harms or benefits associated with these agents. In the meanwhile, we propose these drugs must not be used as treatments for Covid-19 outdoor of clinical trials. he said.


In the current study, the scientists analysed data from 96,032 patients hospitalised between 20 December 2019 and 14 April 2020 with laboratory confirmed SARS-CoV-2 infection from 671 hospitals.



New #COVID19 satisfied

1) Remark: A future vaccination crusade against COVID-19 at risk of vaccine hesitancy and politicisation https://t.co/5EiABOenbi pic.twitter.com/qq7rhoFxyC


— The Lancet Infectious Diseases (@TheLancetInfDis) May 21, 2020


The entire patients included in the study had either been discharged or had died by 21 April 2020, the scientists said.


They compared outcomes from patients treated with chloroquine alone, hydroxychloroquine alone, chloroquine in combination with azithromycin or clarithromycin, or hydroxychloroquine with one of the vital antibiotics.


Patients from these four groups were compared with the remaining keep watch over group of 81,144 patients, the researchers said.


At the end of the study period, around one in 11 patients in the keep watch over group had died in hospital, they said.


ALSO READ: Airlines accept 3-month fare cap, but wish govt didn’t fix pricing


According to the scientists, all four of the treatments were associated with a higher risk of dying in hospital.


The team also found that serious irregular heartbeats called arrhythmias, which cause the lower chamber of the heart to defeat swiftly, were more common in the groups receiving either of the four remedy regimens.


The researchers said around one in six of those treated with chloroquine or hydroxychloroquine alone had died.


When used in combination with one of the vital antibiotics, the study said the death rate rose to a couple of in five for chloroquine, and nearly one in four for hydroxychloroquine.


ALSO READ: Economists, activists propose Mission Jai Hind to take care of Covid-19 crisis


According to the study, probably the most difference in the rates of mortality is because of underlying differences between patients who received the treatments and people who didn’t.


It famous that on accounting for factors like age, race, body weight, and underlying health conditions such as heart disease, lung disease, and diabetes, the drug regimens were associated with an increased risk of death.


The excess risk attributable to using the drug regimen slightly than other factors such as co-morbidities ranged from 34 to 45 per cent, they said.


Whether the rate of mortality is 9.3 per cent in the keep watch over group, the scientists said, on adjustment for other clinical factors, the rate attributable to using the drug regimens would rise to 12.4-13.4 per cent.


Then again, they said it’s not conceivable to exclude the potential for unmeasured factors being responsible for the link.


They said this is because of the design of observational studies, and warned that randomised trials are urgently needed to validate the findings.


While several countries have advocated use of chloroquine and hydroxychloroquine, either alone or in combination, as potential treatments for Covid-19, the evidence that they help patients get better from the disease is small, the scientists concluded.


“Justification for repurposing these medicines in this way is based on a small number of anecdotal experiences that propose they may have recommended effects for people infected with the SARS-CoV-2 virus,” said Frank Ruschitzka from the University Hospital Zurich in Germany, who also co-authored the study.


Ruschitzka said, preceding small-scale studies have also failed to identify robust evidence of a have the benefit of these drugs, adding that larger, randomised controlled trials don’t seem to be yet completed.


“Then again, we now realize from our study that the chance that these medications beef up outcomes in Covid-19 is fairly low, he added.

Top stories / News / Trade

LEAVE A REPLY

Please enter your comment!
Please enter your name here